Atalanta Therapeutics is developing new treatment options for neurodegenerative diseases and other central nervous system (CNS) disorders by utilizing its proprietary RNAi platform, branched siRNA, to target the brain and spinal cord. Named after the mythological Greek heroine and fierce huntress, Atalanta was founded in 2018 by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Chan Medical School (UMMS . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Atalanta Therapeutics’ Branched RNAi Hunts Down Neurodegenerative Diseases appeared first on GEN – Genetic Engineering and Biotechnology News.
